Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Browse

Scholars8,800 Publications201,349 Funding7,267 Clinical research2,831

Loading search results…

Browse

Scholars8,800 Publications201,349 Funding7,267 Clinical research2,831

Filters

Status

Recruiting1,209
Not yet recruiting11
Enrolling by invitation20
Active, not recruiting553
Completed895
Terminated143

Study type

Interventional1,190
Observational101
Expanded access19
Not on ClinicalTrials.gov1,519

Phase

Not reported1,641
Phase 3325
Not applicable304
Phase 2286
Phase 1103
Phase 1/277
Phase 4

Investigator

Gail J Roboz49
Parag Goyal36
Harini Sarva33
Shari Lipner30
Manish A Shah28

Show all 50Show fewer

Department

Medicine1,340
Pediatrics239
Obstetrics and Gynecology150
Radiology137
Population Health Sciences121

Show all 26Show fewer

Condition

Prostatic Neoplasms52
Leukemia, Myeloid, Acute50
Breast Neoplasms43
Heart Failure34
Multiple Myeloma32

Show all 50Show fewer

Intervention type

Drug807
Other202
Device190
Biological157
Procedure127
Behavioral83

Sponsor type

WCM (investigator-initiated)1,383
Industry853
Other academic408
NIH107
Unknown41
Cooperative group35

Start date

Has results posted347

Showing 2761–2780 of 2,831 studiesSort:

CompletedInterventional · Phase 2NCT05669001 ↗
A 12-Month, Randomized, Open-Label, Phase IIA Study Evaluating the Safety and Efficacy of Siplizumab in Combination With Belatacept and MPA Compared to Standard of Care Immunosuppression in de Novo Renal Transplant Recipients (ASCEND)
Darshana M DadhaniaPI
Intervention
Biological: TCD601 · Biological: belatacept · Drug: ATG · Drug: TAC · Drug: MPA · Drug: Corticosteroids
Dates
Dec 2023 – Apr 2026
Sponsor
ITB-MED LLC
Renal Transplantation

Filters

Status

Recruiting1,209
Not yet recruiting11
Enrolling by invitation20
Active, not recruiting553
Completed895
Terminated143

Study type

Interventional1,190
Observational101
Expanded access19
Not on ClinicalTrials.gov1,519

Phase

Not reported1,641
Phase 3325
Not applicable304
Phase 2286
Phase 1103
Phase 1/277
Phase 4

Investigator

Gail J Roboz49
Parag Goyal36
Harini Sarva33
Shari Lipner30
Manish A Shah28

Show all 50Show fewer

Department

Medicine1,340
Pediatrics239
Obstetrics and Gynecology150
Radiology137
Population Health Sciences121

Show all 26Show fewer

Condition

Prostatic Neoplasms52
Leukemia, Myeloid, Acute50
Breast Neoplasms43
Heart Failure34
Multiple Myeloma32

Show all 50Show fewer

Intervention type

Drug807
Other202
Device190
Biological157
Procedure127
Behavioral83

Sponsor type

WCM (investigator-initiated)1,383
Industry853
Other academic408
NIH107
Unknown41
Cooperative group35

Start date

Has results posted347

Showing 2761–2780 of 2,831 studiesSort:

CompletedInterventional · Phase 2NCT05669001 ↗
A 12-Month, Randomized, Open-Label, Phase IIA Study Evaluating the Safety and Efficacy of Siplizumab in Combination With Belatacept and MPA Compared to Standard of Care Immunosuppression in de Novo Renal Transplant Recipients (ASCEND)
Darshana M DadhaniaPI
Intervention
Biological: TCD601 · Biological: belatacept · Drug: ATG · Drug: TAC · Drug: MPA · Drug: Corticosteroids
Dates
Dec 2023 – Apr 2026
Sponsor
ITB-MED LLC
Renal Transplantation

Robert J. Kaner

Alexander Ja-Ho Chou15

Catherine Butkus Small14

Jia Ruan14

Anna Podolanczuk13

Eleni Andreopoulou13

Silvia Chiara Formenti13

Darshana M Dadhania11

Otolaryngology Head and Neck Surgery65

Neurological Surgery59

Cardiothoracic Surgery57

Emergency Medicine48

Anesthesiology46

Pathology and Laboratory Medicine39

Radiation Oncology37

Urology36

Rehabilitation Medicine25

Ophthalmology17

Orthopaedic Surgery11

Systems and Computational Biomedicine11

Genetic Medicine3

Pharmacology3

Biochemistry and Biophysics2

Brain and Mind Research2

Library2

Neoplasms32

Colitis, Ulcerative29

Atrial Fibrillation27

Carcinoma, Non-Small-Cell Lung27

Crohn Disease27

Recurrence27

COVID-1926

Myelodysplastic Syndromes26

Parkinson Disease24

Neoplasm Metastasis23

Obesity23

Colorectal Neoplasms19

HIV Infections19

Hematologic Neoplasms19

Cardiovascular Diseases18

Depression18

Non-alcoholic Fatty Liver Disease16

Overweight15

Lung Neoplasms14

Melanoma14

Cognitive Dysfunction13

Idiopathic Pulmonary Fibrosis13

Inflammatory Bowel Diseases13

Alzheimer Disease12

Leukemia12

Leukemia, Lymphocytic, Chronic, B-Cell12

Lymphoma, Non-Hodgkin12

Primary Myelofibrosis12

Coronary Artery Disease11

Hypertension11

Hypertension, Pulmonary11

Lung Diseases, Interstitial11

Myeloproliferative Disorders11

Pulmonary Arterial Hypertension11

Stroke11

Chronic Pain10

Hemophilia A10

Leukemia, Myelomonocytic, Chronic10

Lymphoma, Follicular10

Lymphoma, Large B-Cell, Diffuse10

Urinary Bladder Neoplasms10

Burkitt Lymphoma9

Fibrosis9

Liver Diseases9

Carcinoma, Renal Cell8

Radiation

Diagnostic test31

Dietary supplement14

Combination product11

Genetic7

Other federal

CompletedInterventional · Phase 2NCT05673811 ↗

A Phase IIb, Open-label, Randomized Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer

Alana NguyenPI

Intervention: Drug: Nab-paclitaxel · Drug: Gemcitabine · Genetic: VCN-01
Dates: Jan 2023 – Mar 2025· Results posted
Sponsor: Theriva Biologics, Inc.

Pancreatic AdenocarcinomaMetastatic

CompletedInterventional · Not applicableNCT05699499 ↗

Analysis of Impact of KeryFlex on Quality of Life for Retronychia or Lichen Planus Adult Patients

Shari LipnerPI

Intervention: Other: KeryFlex
Dates: Apr 2023 – Sep 2023
Sponsor: Weill Medical College of Cornell University

Lichen Planus of Nail

CompletedInterventional · Not applicableNCT05701163 ↗

Assessing the Effect of Abstinence Period on Semen Parameters

Jonathan GalPI

Intervention: Other: Abstinence followed by semen sample collection.
Dates: Apr 2023 – Feb 2028 (est.)
Sponsor: Weill Medical College of Cornell University

Infertility, Male

CompletedInterventional · Phase 3NCT05704738 ↗

A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO)

Andrew F. AlexisPI

Intervention: Drug: Rocatinlimab · Drug: Placebo
Dates: Apr 2023 – Feb 2025· Results posted
Sponsor: Amgen, Inc.

Atopic Dermatitis

CompletedInterventional · Phase 4NCT05711524 ↗

Pilot Clinical Trial of Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen (INTERCEPT Fibrinogen Complex) in Patients With Bleeding to Expedite Product Availability and Improve Outcomes in Perioperative Bleeding

Melissa CushingPI

Intervention: Biological: Traditional Cryoprecipitate · Biological: Pathogen-Reduced Cryoprecipitate
Dates: Apr 2023 – Oct 2024· Results posted
Sponsor: Weill Medical College of Cornell University

HypofibrinogenemiaBleeding

CompletedInterventional · Phase 2NCT05714969 ↗

A Phase 2b, Multicenter, Randomized, Double-blind Study of Safety and Efficacy of TAK-755 (rADAMTS13) With Minimal to No Plasma Exchange (PEX) in the Treatment of Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

Maria Teresa DeSanchoPI

Intervention: Biological: TAK-755
Dates: Jul 2023 – Apr 2026
Sponsor: Takeda Development Center Americas, Inc.

Thrombotic Thrombocytopenic Purpura (TTP)

TerminatedInterventional · Not applicableNCT05747027 ↗

Prospective Randomized Controlled Trial Comparing Transvaginal Rectopexy and Ventral Mesh Rectopexy for Obstructed Defecation in Pelvic Organ Prolapse (PROD Trial)

Tirsit Shiferaw AsfawPI

Intervention: Procedure: Laparoscopic abdominal ventral rectopexy · Procedure: Transvaginal sacrospinous rectopexy
Dates: May 2024 – May 2025· Results posted
Sponsor: NorthShore University Health System

Obstructed DefecationPelvic Organ Prolapse

CompletedInterventional · Phase 3NCT05754957 ↗

A Phase 3, Randomized, Double-blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome

Robert M MinutelloPIDmitriy N. FeldmanPI

Intervention: Drug: Milvexian · Other: Placebo
Dates: Apr 2023 – Feb 2026
Sponsor: Janssen Research & Development, LLC

Acute Coronary Syndrome

CompletedInterventional · Phase 1/2NCT05757570 ↗

Open-Label Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Povetacicept in Subjects With Autoimmune Cytopenias (RUBY-4)

Maria Teresa DeSanchoPI

Intervention: Drug: Povetacicept
Dates: Jul 2023 – Aug 2026
Sponsor: Alpine Immune Sciences, Inc.

Idiopathic Thrombocytopenic PurpuraImmune ThrombocytopeniaWarm Autoimmune Hemolytic Anemia+1 more

CompletedExpanded accessNCT05757973 ↗

64407564MMY4003: 64407564MMY4003 - Talquetamab NPP Global

Ruben NiesvizkyPI

Intervention: Drug: Talquetamab
Dates: Started Jul 2023
Sponsor: Janssen Research & Development, LLC

Relapsed or Refractory Multiple Myeloma

CompletedInterventional · Not applicableNCT05759013 ↗

A Randomized, Sham Controlled, Double-blinded, Multi-center Trial to Evaluate the Efficacy of the VentFree Respiratory Muscle Stimulator to Assist Ventilator Weaning in Critically Ill Patients

Lisa K TorresPI

Intervention: Device: Breath synchronized abdominal FES · Device: Sham breath synchronized abdominal FES
Dates: Feb 2024 – Feb 2026
Sponsor: Liberate Medical LLC

Respiration, ArtificialVentilators, Mechanical

CompletedInterventional · Phase 4NCT05767749 ↗

Characterizing and Comparing the Duration of Local Anesthetic in Dermatologic Surgery

Kira MinkisPILisa M KernPI

Intervention: Drug: lidocaine + epinephrine 1:100,000 · Drug: Ropivacaine 0.5% Injectable Solution · Drug: Bupivacaine 0.5% Injectable Solution
Dates: Mar 2023 – Jul 2023· Results posted
Sponsor: Weill Medical College of Cornell University

Anesthetics, Local

CompletedInterventional · Phase 2/3NCT05769582 ↗

Safety, Tolerability and Efficacy of AntiBKV as Treatment of BKV Infection in Kidney Transplant Recipients, a Randomized Phase II/III Study, Double-blind and Placebo-controlled

Darshana M DadhaniaPI

Intervention: Biological: Anti-BK polyomavirus (AntiBKV)
Dates: Apr 2023 – Mar 2025
Sponsor: Memo Therapeutics AG

BK ViremiaBKV DNAemia

TerminatedObservationalNCT05780736 ↗

Prospective Evaluation of Nivolumab in Adjuvant Esophageal Carcinoma/Gastroesophageal Junction Carcinoma: A Non-interventional Study

Manish A ShahPI

Dates: Aug 2023 – Aug 2024
Sponsor: Bristol-Myers Squibb Company

Esophageal CarcinomaGastroesophageal Junction Carcinoma

TerminatedInterventional · Phase 1NCT05787496 ↗

A Phase 1, Open-Label, Safety, Tolerability, And Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms

Pinkal DesaiPI

Intervention: Drug: NC525
Dates: Feb 2023 – Jan 2025· Results posted
Sponsor: NextCure, Inc.

Relapsed or Refractory Acute Myeloid LeukemiaRelapsed or Refractory Chronic Myelomonocytic LeukemiaRelapsed or Refractory Myelodysplastic Syndrome

CompletedInterventional · Phase 4NCT05796557 ↗

ECMO Hemostatic Transfusions in Children

Marianne Elizabeth NellisPI

Intervention: Biological: Platelet Transfusion
Dates: Dec 2023 – Jan 2025· Results posted
Sponsor: Yale University

Extracorporeal Membrane Oxygenation ComplicationHemorrhageThromboembolism+1 more

CompletedInterventional · Phase 2NCT05819359 ↗

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects With Parkinson's Disease With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene

Harini SarvaPI

Intervention: Drug: BIA 28-6156 10 mg · Drug: BIA 28-6156 60 mg · Drug: Placebo
Dates: Mar 2023 – Apr 2026
Sponsor: BIAL R&D Investments S.A.

Parkinson's Disease

CompletedInterventional · Phase 4NCT05822583 ↗

Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial

Matthew William McCarthyPIAlexander DrelickPI

Intervention: Drug: abatacept infusion · Drug: Placebo group
Dates: Jul 2023 – Jun 2025· Results posted
Sponsor: University of Minnesota

COVID-19

CompletedInterventional · Phase 3NCT05822830 ↗

A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide in Adults Who Have Obesity or Overweight With Weight Related Comorbidities

Alpana P. ShuklaPI

Intervention: Drug: Tirzepatide · Drug: Semaglutide
Dates: Apr 2023 – Nov 2024· Results posted
Sponsor: Eli Lilly and Company

ObesityOverweight

‹ Prev 1 2 3 4 5…138 139 140 141 142 Next ›